Compositions relating to a mutant Clostridium difficile toxin and methods thereof

Patent metadata

Field	Value
Publication number	US-9745354-B2
Application number	US-201414529147-A
Country	US
Kind code	B2
Filing date	Oct 31, 2014
Priority date	Apr 22, 2011
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

First claim

The invention claimed is:

1. A method of producing an immunogenic and mutant Clostridium difficile toxin comprising contacting a peptide derived from a Clostridium difficile toxin with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC) for at most 2 hours, contacting the peptide with N-hydroxysuccinimide (NHS); and purifying the EDC-contacted and NHS-contacted peptide, wherein the step of purifying comprises filtration.

2. The method of claim 1 , further comprising contacting the peptide with glycine.

3. The method of claim 1 , further comprising contacting the peptide with alanine or glycine methyl ester.

4. The method of claim 1 , wherein the peptide comprises at least one lysine residue.

5. The method of claim 1 , wherein the peptide comprises at least one aspartic acid residue or at least one glutamic acid residue.

6. The method of claim 1 , wherein the peptide comprises at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2.

7. The method of claim 6 , further comprising contacting a second peptide, having at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2, with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC).

8. The method of claim 1 , wherein the peptide comprises at least one mutation relative to the corresponding wild-type Clostridium difficile toxin.

9. The method of claim 1 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 4, wherein the methionine at position 1 is not present.

10. The method of claim 1 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 6, wherein the methionine at position 1 is not present.

11. A method of producing an immunogenic and mutant Clostridium difficile toxin comprising contacting a peptide derived from a Clostridium difficile toxin with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC), contacting the peptide with N-hydroxysuccinimide (NHS); further contacting the peptide with glycine; and purifying the EDC-contacted, NHS-contacted, and glycine-contacted peptide, wherein the step of purifying comprises filtration.

12. The method of claim 11 , wherein the contacting occurs for at most 2 hours.

13. The method of claim 11 , wherein the peptide comprises at least one lysine residue.

14. The method of claim 11 , wherein the peptide comprises at least one aspartic acid residue or at least one glutamic acid residue.

15. The method of claim 11 , wherein the peptide comprises at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2.

16. The method of claim 15 , further comprising contacting a second peptide, having at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2, with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC).

17. The method of claim 11 , wherein the peptide comprises at least one mutation relative to the corresponding wild-type Clostridium difficile toxin.

18. The method of claim 11 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 4, wherein the methionine at position 1 is not present.

19. The method of claim 11 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 6, wherein the methionine at position 1 is not present.

20. A method of producing an immunogenic and mutant Clostridium difficile toxin comprising contacting a peptide derived from a Clostridium difficile toxin with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC), contacting the peptide with N-hydroxysuccinimide (NHS); further contacting the peptide with alanine or glycine methyl ester; and purifying the EDC-contacted, NHS-contacted, and alanine- or glycine methyl ester-contacted peptide, wherein the step of purifying comprises filtration.

21. The method of claim 20 , wherein the contacting occurs for at most 2 hours.

22. The method of claim 20 , wherein the peptide comprises at least one lysine residue.

23. The method of claim 20 , wherein the peptide comprises at least one aspartic acid residue or at least one glutamic acid residue.

24. The method of claim 20 , wherein the peptide comprises at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2.

25. The method of claim 24 , further comprising contacting a second peptide, having at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2, with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC).

26. The method of claim 20 , wherein the peptide comprises at least one mutation relative to the corresponding wild-type Clostridium difficile toxin.

27. The method of claim 20 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 4, wherein the methionine at position 1 is not present.

28. The method of claim 20 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 6, wherein the methionine at position 1 is not present.

Assignees

• Wyeth Llc

Inventors

• Ruppen Mark E
• Moran Justin Keith
• Jansen Kathrin Ute
• Anderson Annaliesa Sybil
• Donald Robert G K
• Kalyan Narender K
• Sidhu Maninder K
• Flint Michael James

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• C12N9/1051

  Hexosyltransferases (2.4.1) · CPC title